Chemistry: molecular biology and microbiology – Treatment of micro-organisms or enzymes with electrical or... – Modification of viruses
Patent
1994-11-28
1997-06-24
Stanton, Brian R.
Chemistry: molecular biology and microbiology
Treatment of micro-organisms or enzymes with electrical or...
Modification of viruses
435 6952, 435325, 435243, 4353201, 435348, 43525233, 514 44, 530351, 536 241, A61K 4800, C07K 1455, C12N 1500, C12N 1526
Patent
active
056416652
ABSTRACT:
The present invention relates to plasmids suitable for IL-2 expression, particularly, human IL-2 expression, and related methods.
REFERENCES:
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4992367 (1991-02-01), Cullen
patent: 5122458 (1992-06-01), Post et al.
patent: 5168062 (1992-12-01), Stinski
Vile, R.G. & Hart, I.R., "Targeting of Cytokine Gene Expression to Malignant Melanoma Cells Using Tissue Specific Promoter Sequences", Annals of Oncology 5(Supp. 4), 1994 pp. 559-565.
Lewin, R. "When Does Homology Mean Something Else?" Science 237, 1570 (1987).
Reeck, G.R. et. al. "Homology in Proteins and Nucleic Acids: A Terminology Muddle and a Way Out of It" Cell 50, 667 (1987).
Manthorpe, M. et. al. "Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies in Firefly Luciferase Gene Expression in Mice", Human Gene Therapy 4, 419-431 (1993).
Wardley, R.C. et al. "The Use of Feline Herpesvirus and Baculovirus as Vaccine Vectors for the gag and env Genes of Feline Leukemia Virus" J. of General Virology 43, 1811-1818 (1992).
Plautz, G.E. et al "Immunotherapy of Malignancy by in Vivo Gene Transfer Into Tumors". PNAS 90, 4645-4649 (1993).
Nabel, G.J. "Direct Gene Transfer with DNA-Liposome Complexes in Melanoma: Expression Biologic Activity, and Lack of Toxicity in Humans" PNAS 90, 11307-11311 (1993).
Gansbucher et. al. "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity" J. Exp. Med. 172, 1217-1224 (1990).
Gansbucher et al "Retroviral Gene Transfer Induced Constitutive Expression of Interleukin-2 or Interferon-.gamma. in Irradiated Human Melanoma Cells" Blood 11, 2817.
San et al "Safety and Short-Term Toxicity of a Novel Cationic Lipid Formulation for Human Gene Therapy" Human Gene Therapy 4, 781-788 (1993).
Orkin and Motulsky, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", Dec. 7, 1995.
Margalith, M., et al. (1995) VCL1102: A plasmid DNA vector to effect high levels of IL-2 expression in vivo. Journal of Cellular Biochemistry Supplement 21A, see abstract C6-534.
Montogomery, D., et al. (1993) Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA and Cell Biology 12(9): 777-783.
Nabel, G., et al. (1994) Immunotherapy for cancer by direct gene transfer into tumors. Human Gene Therapy 5:57-77.
Parker, S., et al. (1994) Direct delivery of cytokine genes into tumors for cancer immunotherapy. Journal of Cellular Biochemistry Supplement 18A, see abstract DZ 414.
San, H., et al. (1993) Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Human Gene Therapy 4:781-788.
Berg, D. et al. (1978) In Microbiology [Schelessinger. D. ed.] pp. 13-15 American Society for Microbiology, Washington D.C.
Bolivar, F. et al. (1977) Construction and characterization of new cloning vehicles II. A multipurpose cloning system. Gene 2:95-113.
Chapman, B. et al. (1991) Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Research 19(14):3979-3986.
Cullen, B. et al. (1988) Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a heterologous mRNA leader region. DNA 7(9) 645-650.
LaFemina, R. et al. (1980) Structural organization of the DNA molecules from human cytomegalovirus. Animal Virus Genetics 39-55.
Oka, A. et al. (1981) Nucleotide sequence of the kanamycin resistance transposon Tn903. J. Mol. Biol. 147:217-226.
O'Quigley, J. et al. (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
O'Quigley, J. et al. (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a monte carlo study. Statistics in Medicine 10:1647-1664.
Storer, B. (1989) Design and analysis of phase I clinical trial. Biometrics 45:925-937.
Hobart Peter M.
Khatibi Shirin
Margalith Michal
Parker Suezanne E.
Axelrod Nancy
Stanton Brian R.
Vical Incorporated
LandOfFree
Plasmids suitable for IL-2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plasmids suitable for IL-2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasmids suitable for IL-2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-148611